Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study

Wood, 1998, Prevention of coronary heart disease in clinical practice, Eur Heart J, 19, 1434, 10.1053/euhj.1998.1243 2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 2001, Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries, Eur Heart J, 22, 554, 10.1053/euhj.2001.2610 Pearson, 2000, The Lipid Treatment Assessment Project (L-TAP), Arch Intern Med, 160, 459, 10.1001/archinte.160.4.459 Sueta, 1999, Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease, Am J Cardiol, 83, 1303, 10.1016/S0002-9149(99)00117-4 Jones, 1998, Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study), Am J Cardiol, 81, 582, 10.1016/S0002-9149(97)00965-X Andrews, 2001, Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins, Am J Med, 111, 185, 10.1016/S0002-9343(01)00799-9 Jones, 2003, Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial), Am J Cardiol, 92, 152, 10.1016/S0002-9149(03)00530-7 Paoletti, 2001, Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients, J Cardiovasc Risk, 8, 383, 10.1177/174182670100800608 Davidson, 2002, Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia, Am J Cardiol, 89, 268, 10.1016/S0002-9149(01)02226-3 Olsson, 2002, Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia, Am Heart J, 144, 1044, 10.1067/mhj.2002.128049 Brown, 2002, Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia, Am Heart J, 144, 1036, 10.1067/mhj.2002.129312 Schneck, 2003, Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease, Am J Cardiol, 91, 33, 10.1016/S0002-9149(02)02994-6 Remmell, 1980, Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT), I, J Am Diet Assoc, 76, 351, 10.1016/S0002-8223(21)05246-9 Myers, 1989, The Centers for Disease Control–National Heart, Lung and Blood Institute Lipid Standardization Program, Clin Lab Med, 9, 105, 10.1016/S0272-2712(18)30645-0 Steiner, 1981, Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the clinics' methodology, J Clin Chem Biochem, 19, 850 Hainline A Jr, Karon J, Lippel K, editors. Lipid Research Clinics Program manual of laboratory operations: lipid and lipoprotein analysis. 2nd ed. Bethesda (Md): National Heart, Lung and Blood Institute; 1982. NIH Publication No. 75-628 (revised) Warnick, 1978, A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol, J Lipid Res, 19, 65, 10.1016/S0022-2275(20)41577-9 Miller, 1981 Hunninghake, 1998, Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease, J Fam Pract, 47, 349 Brown, 1998, Treating patients with documented atherosclerosis to National Cholesterol Education Program–recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin, J Am Coll Cardiol, 32, 665, 10.1016/S0735-1097(98)00300-3 Shepherd, 2003, Guidelines for lowering lipids to reduce coronary artery disease risks, Am J Cardiol, 91, 11, 10.1016/S0002-9149(03)00004-3 Hilleman, 2001, Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease, Pharmacotherapy, 21, 410, 10.1592/phco.21.5.410.34491 van Dam, 2000, Additional efficacy of milligram-equivalent doses of atorvastatin over simvastatin, Clin Drug Invest, 19, 327, 10.2165/00044011-200019050-00002 Taylor, 2001, Lipid-lowering efficacy, safety, and costs of a large-scale therapeutic statin formulary conversion program, Pharmacotherapy, 21, 1130, 10.1592/phco.21.13.1130.34616 Blasetto, 2003, Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups, Am J Cardiol, 91, 3, 10.1016/S0002-9149(03)00003-1